Constipated irritable bowel syndrome
Conditions
Interventions
Control group:Patients were administered Mosapride Citrate Tablets (Chengdu Kanghong Pharmaceutical Group Co., Ltd., National Drug Approval No. H20031110, 5 mg/tablet), 3 times daily, 1 tablet each ti
Monotherapy group:In addition to the basic regimen of the control group, patients received lactulose oral solution (66.7 g/100 mL, manufactured by Dumex, Abbott Healthcare, USA), at a dosage of 10 mL,
Combination group:In addition to the regimen of the monotherapy group (basic treatment + lactulose), patients received Lactobacillus rhamnosus GG (LGG) powder (Jingchangle, produced by Zhejiang Jingxi
containing >=1.0×10^9 CFU/g of viable bacteria) at a dosage of 500 mg, three times daily.
Sponsors
Taishan Hospital of Shandong Province
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: According to the 2006 Rome ? criteria, abdominal pain, abdominal distension and abdominal discomfort had been present for at least 6 months and recurred in the past 3 months, and at least 2 of the following symptoms had been present for at least 3 days per month in the past 3 months: 1. Symptoms improved after defecation. 2. Seizures accompanied by changes in defecation frequency; 3. Defecation less than 3 times per week; 4. Lumpy stool/hard stool; 5. Feeling of incomplete defecation; 6. Bloating.
Exclusion criteria
Exclusion criteria: 1. Intestinal organic diseases such as intestinal cancer, intestinal tuberculosis and ulcerative colitis; 2. Endocrine, drug-induced and neurogenic constipation; 3. No laxatives were used 3 months before treatment, which affected gastrointestinal motility drugs, digestive enzymes, and probiotics preparations.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical efficacy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Bristol Bowel Scale;Irritable bowel syndrome Quality of life score;Perceived Stress Scale;Irritable bowel syndrome severity scoring system;Gut microbiota;Gastrointestinal hormones;Safety observation; | — |
Countries
China
Contacts
Public ContactWu Rongfang
Taishan Hospital of Shandong Province
Outcome results
None listed